

Christos S Karapetis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8014876/publications.pdf>

Version: 2024-02-01

89
papers

8,045
citations

186265

28
h-index

69250

77
g-index

90
all docs

90
docs citations

90
times ranked

9655
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. <i>British Journal of Cancer</i> , 2022, 126, 42-47.	6.4	34
2	Investigating the breast cancer screeningâ€“treatmentâ€“mortality pathway of women diagnosed with invasive breast cancer: Results from linked health data. <i>European Journal of Cancer Care</i> , 2022, 31, e13539.	1.5	2
3	Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990â€“2017. <i>Cancers</i> , 2022, 14, 275.	3.7	8
4	Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. <i>Journal of Thoracic Oncology</i> , 2022, 17, 758-767.	1.1	22
5	Immunotherapy use in oesophagogastric cancersâ€“a review of the literature. <i>British Journal of Cancer</i> , 2022, 127, 21-29.	6.4	2
6	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. <i>BMC Cancer</i> , 2022, 22, 222.	2.6	3
7	Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. <i>Supportive Care in Cancer</i> , 2022, 30, 8217-8229.	2.2	4
8	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	5.1	77
9	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637.	2.0	11
10	Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 52-59.	7.0	12
11	Australia and New Zealand's responsibilities in improving oncology services in the Asiaâ€“Pacific: A call to action. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	1.1	6
12	Female breast cancer treatment and survival in South Australia: Results from linked health data. <i>European Journal of Cancer Care</i> , 2021, 30, e13451.	1.5	3
13	A collaborative approach to meeting oncology challenges in island communities in the Asiaâ€“Pacific region. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 418-423.	1.8	1
14	Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 39-52.	2.3	1
15	Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5547.	4.1	9
16	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	8.4	88
17	Second-line FOLFOX chemotherapy for advanced biliary tract cancer. <i>Lancet Oncology</i> , The, 2021, 22, e286.	10.7	0
18	Evaluation of pharmacogenomics and hepatic nuclear imagingâ€“related covariates by population pharmacokinetic models of irinotecan and its metabolites. <i>European Journal of Clinical Pharmacology</i> , 2021, , 1.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Patterns of care and outcomes for gastric and gastrooesophageal junction cancer in an Australian population. ANZ Journal of Surgery, 2021, , .	0.7	2
20	Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e139-e145.	1.1	6
21	Dose modification for haematological toxicity: a survey of Australian medical oncologists. Internal Medicine Journal, 2020, 50, 1338-1343.	0.8	1
22	Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. European Urology, 2020, 78, 540-543.	1.9	70
23	MicroRNA Profiling in Oesophageal Adenocarcinoma Cell Lines and Patient Serum Samples Reveals a Role for miR-451a in Radiation Resistance. International Journal of Molecular Sciences, 2020, 21, 8898.	4.1	9
24	Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Clinical Cancer Research, 2020, 26, 5487-5493.	7.0	65
25	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. JCO Oncology Practice, 2020, 16, 467-482.	2.9	56
26	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	2.4	4
27	Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. Clinical Cancer Research, 2020, 26, 3280-3286.	7.0	28
28	Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. Targeted Oncology, 2019, 14, 743-748.	3.6	6
29	Cardiotoxicity after cancer treatment: a process map of the patient treatment journey. Cardio-Oncology, 2019, 5, 14.	1.7	14
30	Pre-diagnostic colonoscopies reduce cancer mortality - results from linked population-based data in South Australia. BMC Cancer, 2019, 19, 856.	2.6	10
31	Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC. Journal of Thoracic Oncology, 2019, 14, e208.	1.1	1
32	Author's Reply. Journal of Thoracic Oncology, 2019, 14, e210.	1.1	0
33	Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. Journal of Thoracic Oncology, 2019, 14, 1440-1446.	1.1	73
34	Authors' Reply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry" Targeted Oncology, 2019, 14, 367-368.	3.6	0
35	Internet use and preferences among women living with advanced breast cancer. Breast Journal, 2019, 25, 290-295.	1.0	9
36	Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. Journal of Thoracic Disease, 2019, 11, 4241-4248.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). <i>EBioMedicine</i> , 2019, 50, 433-441.	6.1	32
38	The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 1118.	2.3	63
39	Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019, 18, e140-e149.	2.3	5
40	Online information and support needs of women with advanced breast cancer: a qualitative analysis. <i>Supportive Care in Cancer</i> , 2018, 26, 3489-3496.	2.2	38
41	Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e64-e70.	1.1	11
42	Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases". <i>Annals of Surgery</i> , 2018, 268, e9-e10.	4.2	0
43	Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer. <i>Annals of Surgery</i> , 2018, 267, 929-935.	4.2	3
44	Acanthosis Palmaris: A Rare Paraneoplastic Manifestation of Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 331-332.	2.5	0
45	Author reply. <i>Internal Medicine Journal</i> , 2018, 48, 1415-1416.	0.8	0
46	Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. <i>Cancers</i> , 2018, 10, 384.	3.7	9
47	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018, 57, 1438-1444.	1.8	78
48	Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. <i>Internal Medicine Journal</i> , 2018, 48, 774-779.	0.8	22
49	Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing. <i>Annals of Surgical Oncology</i> , 2018, 25, 2731-2738.	1.5	18
50	Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1741-1750.	2.5	38
51	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3838-3844.	7.0	7
52	The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 275.	2.8	27
53	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	2.3	9
54	Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 135-144.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Serum vitamin D decreases during chemotherapy: an Australian prospective cohort study. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2018, 27, 962-967.	0.4	2
56	Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. <i>Internal Medicine Journal</i> , 2017, 47, 408-414.	0.8	9
57	Female breast cancer management and survival: The experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 1433-1443.	1.8	5
58	Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1041.	4.1	8
59	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
60	Fc- γ 3 Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2435-2444.	7.0	33
61	Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. <i>Annals of Surgical Oncology</i> , 2016, 23, 3616-3622.	1.5	16
62	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. <i>European Journal of Cancer</i> , 2016, 55, 122-130.	2.8	32
63	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 95-103.	2.3	30
64	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 557-571.	2.4	7
65	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 75-82.	3.8	7
66	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. <i>Clinical Colorectal Cancer</i> , 2016, 15, 32-36.	2.3	37
67	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015, 10, e0135599.	2.5	22
68	Colorectal cancer: Metastases to a single organ. <i>World Journal of Gastroenterology</i> , 2015, 21, 11767.	3.3	233
69	Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. <i>Cancer Medicine</i> , 2015, 4, 1461-1471.	2.8	17
70	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1033-1048.	3.1	0
71	Reply: Comment on "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer". <i>British Journal of Cancer</i> , 2015, 113, 1635-1635.	6.4	127
72	Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. <i>Medical Journal of Australia</i> , 2014, 201, 462-466.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493.	2.4	12
74	PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 2014, 20, 744-753.	7.0	140
75	Colorectal Cancer Survival: An Analysis of Patients With Metastatic Disease Synchronous and Metachronous With the Primary Tumor. Clinical Colorectal Cancer, 2014, 13, 87-93.	2.3	50
76	Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 597-611.	2.4	30
77	A population-based study of metastatic colorectal cancer in individuals aged ≥80 years. Cancer, 2013, 119, 722-728.	4.1	39
78	Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the KRAS Gene in Patients with Metastatic Colorectal Cancer: Analysis of the NCIC CTG CO.17 Trial. Archives of Pathology and Laboratory Medicine, 2013, 137, 820-827.	2.5	27
79	Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Management and Research, 2013, 5, 387.	1.9	17
80	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. Colorectal Cancer, 2012, 1, 137-148.	0.8	1
81	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 2012, 48, 1293-1298.	2.8	28
82	A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 298-305.	1.1	5
83	Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA - Journal of the American Medical Association, 2010, 304, 1812.	7.4	663
84	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 2010, 9, 8-14.	2.3	7
85	Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 2009, 27, 1822-1828.	1.6	106
86	Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable?. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 24-31.	1.1	0
87	Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 2009, 101, 1182-1192.	6.3	119
88	K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 2008, 359, 1757-1765.	27.0	3,353
89	Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 2007, 357, 2040-2048.	27.0	1,778